Cargando…

E-site drug specificity of the human pathogen Candida albicans ribosome

Candida albicans is a widespread commensal fungus with substantial pathogenic potential and steadily increasing resistance to current antifungal drugs. It is known to be resistant to cycloheximide (CHX) that binds to the E–transfer RNA binding site of the ribosome. Because of lack of structural info...

Descripción completa

Detalles Bibliográficos
Autores principales: Zgadzay, Yury, Kolosova, Olga, Stetsenko, Artem, Wu, Cheng, Bruchlen, David, Usachev, Konstantin, Validov, Shamil, Jenner, Lasse, Rogachev, Andrey, Yusupova, Gulnara, Sachs, Matthew S., Guskov, Albert, Yusupov, Marat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132455/
https://www.ncbi.nlm.nih.gov/pubmed/35613268
http://dx.doi.org/10.1126/sciadv.abn1062
_version_ 1784713382439419904
author Zgadzay, Yury
Kolosova, Olga
Stetsenko, Artem
Wu, Cheng
Bruchlen, David
Usachev, Konstantin
Validov, Shamil
Jenner, Lasse
Rogachev, Andrey
Yusupova, Gulnara
Sachs, Matthew S.
Guskov, Albert
Yusupov, Marat
author_facet Zgadzay, Yury
Kolosova, Olga
Stetsenko, Artem
Wu, Cheng
Bruchlen, David
Usachev, Konstantin
Validov, Shamil
Jenner, Lasse
Rogachev, Andrey
Yusupova, Gulnara
Sachs, Matthew S.
Guskov, Albert
Yusupov, Marat
author_sort Zgadzay, Yury
collection PubMed
description Candida albicans is a widespread commensal fungus with substantial pathogenic potential and steadily increasing resistance to current antifungal drugs. It is known to be resistant to cycloheximide (CHX) that binds to the E–transfer RNA binding site of the ribosome. Because of lack of structural information, it is neither possible to understand the nature of the resistance nor to develop novel inhibitors. To overcome this issue, we determined the structure of the vacant C. albicans 80S ribosome at 2.3 angstroms and its complexes with bound inhibitors at resolutions better than 2.9 angstroms using cryo–electron microscopy. Our structures reveal how a change in a conserved amino acid in ribosomal protein eL42 explains CHX resistance in C. albicans and forms a basis for further antifungal drug development.
format Online
Article
Text
id pubmed-9132455
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-91324552022-06-01 E-site drug specificity of the human pathogen Candida albicans ribosome Zgadzay, Yury Kolosova, Olga Stetsenko, Artem Wu, Cheng Bruchlen, David Usachev, Konstantin Validov, Shamil Jenner, Lasse Rogachev, Andrey Yusupova, Gulnara Sachs, Matthew S. Guskov, Albert Yusupov, Marat Sci Adv Biomedicine and Life Sciences Candida albicans is a widespread commensal fungus with substantial pathogenic potential and steadily increasing resistance to current antifungal drugs. It is known to be resistant to cycloheximide (CHX) that binds to the E–transfer RNA binding site of the ribosome. Because of lack of structural information, it is neither possible to understand the nature of the resistance nor to develop novel inhibitors. To overcome this issue, we determined the structure of the vacant C. albicans 80S ribosome at 2.3 angstroms and its complexes with bound inhibitors at resolutions better than 2.9 angstroms using cryo–electron microscopy. Our structures reveal how a change in a conserved amino acid in ribosomal protein eL42 explains CHX resistance in C. albicans and forms a basis for further antifungal drug development. American Association for the Advancement of Science 2022-05-25 /pmc/articles/PMC9132455/ /pubmed/35613268 http://dx.doi.org/10.1126/sciadv.abn1062 Text en Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.
spellingShingle Biomedicine and Life Sciences
Zgadzay, Yury
Kolosova, Olga
Stetsenko, Artem
Wu, Cheng
Bruchlen, David
Usachev, Konstantin
Validov, Shamil
Jenner, Lasse
Rogachev, Andrey
Yusupova, Gulnara
Sachs, Matthew S.
Guskov, Albert
Yusupov, Marat
E-site drug specificity of the human pathogen Candida albicans ribosome
title E-site drug specificity of the human pathogen Candida albicans ribosome
title_full E-site drug specificity of the human pathogen Candida albicans ribosome
title_fullStr E-site drug specificity of the human pathogen Candida albicans ribosome
title_full_unstemmed E-site drug specificity of the human pathogen Candida albicans ribosome
title_short E-site drug specificity of the human pathogen Candida albicans ribosome
title_sort e-site drug specificity of the human pathogen candida albicans ribosome
topic Biomedicine and Life Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132455/
https://www.ncbi.nlm.nih.gov/pubmed/35613268
http://dx.doi.org/10.1126/sciadv.abn1062
work_keys_str_mv AT zgadzayyury esitedrugspecificityofthehumanpathogencandidaalbicansribosome
AT kolosovaolga esitedrugspecificityofthehumanpathogencandidaalbicansribosome
AT stetsenkoartem esitedrugspecificityofthehumanpathogencandidaalbicansribosome
AT wucheng esitedrugspecificityofthehumanpathogencandidaalbicansribosome
AT bruchlendavid esitedrugspecificityofthehumanpathogencandidaalbicansribosome
AT usachevkonstantin esitedrugspecificityofthehumanpathogencandidaalbicansribosome
AT validovshamil esitedrugspecificityofthehumanpathogencandidaalbicansribosome
AT jennerlasse esitedrugspecificityofthehumanpathogencandidaalbicansribosome
AT rogachevandrey esitedrugspecificityofthehumanpathogencandidaalbicansribosome
AT yusupovagulnara esitedrugspecificityofthehumanpathogencandidaalbicansribosome
AT sachsmatthews esitedrugspecificityofthehumanpathogencandidaalbicansribosome
AT guskovalbert esitedrugspecificityofthehumanpathogencandidaalbicansribosome
AT yusupovmarat esitedrugspecificityofthehumanpathogencandidaalbicansribosome